Skip to main content
. 2022 Jun 23;6:e2200009. doi: 10.1200/PO.22.00009

FIG 2.

FIG 2.

MRI of the abdomen/pelvis (T2-weighted, postgadolinium, LAVA) demonstrating progression of hepatic metastases on TMZ followed by partial response to pembrolizumab immunotherapy. Representative images (A) during treatment holiday before the last three cycles of TMZ/capecitabine (maximum lesion diameter: 7.3 cm); (B) after three cycles of carboplatin/etoposide, before initiation of pembrolizumab (maximum lesion diameter: 9.0 cm); (C) after eight cycles of pembrolizumab (maximum lesion diameter: 4.4 cm); and (D) after 12 cycles (9 months) of pembrolizumab (maximum lesion diameter: 7.0 cm). LAVA, liver acquisition volume acceleration; MRI, magnetic resonance imaging; TMZ, temozolomide.